Lung Cancer Indicator Detection

NCT02612532 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 2603

Last updated 2023-06-18

No results posted yet for this study

Summary

The Lung Cancer Indicator Detection (LuCID) study investigates the the diagnostic accuracy of FAIMS for diagnosis of lung cancer by analysis of exhaled Volatile Organic Compounds.

Conditions

Interventions

DEVICE

ReCIVA breath sampler

Device developed for standardised collection of breath samples http://www.owlstonenanotech.com/medical/products/reciva

Sponsors & Collaborators

  • Papworth Hospital NHS Foundation Trust

    collaborator OTHER_GOV
  • University Hospitals, Leicester

    collaborator OTHER
  • University College, London

    collaborator OTHER
  • Universitätsklinikum Leipzig

    collaborator OTHER
  • University Hospital, Antwerp

    collaborator OTHER
  • University Hospital, Ghent

    collaborator OTHER
  • University of Bari

    collaborator OTHER
  • University of Athens

    collaborator OTHER
  • Glenfield Hospital

    collaborator OTHER
  • Peterborough and Stamford Hospitals NHS Foundation Trust

    collaborator OTHER
  • University Hospitals of North Midlands NHS Trust

    collaborator OTHER
  • Manchester University NHS Foundation Trust

    collaborator OTHER_GOV
  • University Hospital Southampton NHS Foundation Trust

    collaborator OTHER
  • Buckinghamshire Healthcare NHS Trust

    collaborator OTHER
  • Wirral University Teaching Hospital NHS Trust

    collaborator OTHER
  • South Tyneside and Sunderland NHS Foundation Trust

    collaborator OTHER
  • Liverpool University Hospitals NHS Foundation Trust

    collaborator OTHER_GOV
  • Clinical Research and Trials Unit (Norfolk & Norwich University Hospital, UK)

    collaborator OTHER
  • Barnet and Chase Farm Hospitals NHS Trust

    collaborator OTHER
  • Liverpool Heart and Chest Hospital NHS Foundation Trust

    collaborator OTHER
  • Owlstone Ltd

    lead INDUSTRY

Principal Investigators

  • Marc P van der Schee, MD, PhD · Owlstone Medical

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-10-07
Primary Completion
2021-03-31
Completion
2022-12-22

Countries

  • Belgium
  • Germany
  • Italy
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02612532 on ClinicalTrials.gov